Dr. Khan's research focuses on understanding the apoptosis mechanisms in cancer cells and targeting BCL-2 family proteins (e.g., BCL-xL and BCL-2), by using Proteolysis-Targeting chimeras (PROTACs) for effective cancer therapy and reduced toxicity. In addition, Dr. Khan studies the mechanisms of drug resistance and develop strategies for therapeutic sensitization by using BCL-xL PROTACs and other targeted or chemotherapeutic drugs for combination therapy. His other research interests are targeting senescenct cells for improved cancer therpay, and drug repurposing. Dr. Khan’s primary disease area of interest is pancreatic cancer, with secondary interests in colorectal cancer, lung cancer and breast cancer.